News - Biotechnology
Wyoming senators reap largesse from biotechnology firm Amgen
29 January 2013
A California biotechnology company set to benefit by millions of dollars from a last-minute addition to the January 1 ?Fiscal Cliff? bill is among the top campaign contributors to Wyoming U.S. Senators Mike Enzi and John Barrasso. Both senators were ...
Click on the link to read the full article at WyoFile (This link will open in a new window)Indo-Spanish joint programme for technological cooperation in biotechnology ...
29 January 2013
India and Spain have announced a joint programme for technological co-operation between Department of Biotechnology (DBT) and Centre for the Development of Industrial Technology (CDTI) of Spain, at the inauguration of 10th edition of BioAsia summit in ...
Click on the link to read the full article at pharmabiz.com (This link will open in a new window)National workshop on fundamentals of nanoscience and biotechnology
28 January 2013
A three-day national level workshop on fundamentals of nanoscience and biotechnology began in the department of bioengineering, Integral University on Monday. The workshop is being organised by Department of nano-biotechnology Life Science ...
Click on the link to read the full article at Times of India (This link will open in a new window)Immunovative, Inc. Actively Seeking Potential Acquisition Targets in the ...
28 January 2013
NEW YORK, NY--(Marketwire - Jan 28, 2013) - Immunovative, Inc. ( OTCQB : IMUN) ("IMUN" or "The Company") today announced that the Company is actively seeking potential acquisition targets in the biotechnology sector. The Company is hopeful that ...
Click on the link to read the full article at Marketwire (press release) (This link will open in a new window)Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice ...
28 January 2013
CLEVELAND, Jan. 28, 2013 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease announced today that Paul Resnick , M.D., M.B.A., ...
Click on the link to read the full article at PR Newswire (press release) (This link will open in a new window)Biotechnology needs more govt support
28 January 2013
ISLAMABAD - Limited resources, inadequate stock of trained manpower and lack of proper coordination among the institutions are some of the reasons, owing to which biotechnology sector has not been developed to its full potential. As a cross cutting ...
Click on the link to read the full article at The Nation (This link will open in a new window)Biotechnology goes to Congress in PHL
26 January 2013
The developments in biotechnology in the Philippines were discussed when the offices of Rep. Angelo Palmones of Agham Party-list and Rep. Agapito Guanlao of Butil Party-list, the house committees on Science and Technology, Agriculture and Food, and ...
Click on the link to read the full article at Business Mirror (This link will open in a new window)Biotechnology startup developing remedy to reduce Parkinson's disease drug ...
25 January 2013
MentiNova's oral drug would curb dyskenesia the involuntary movements caused by long-term use of levodopa, or L-Dopa, a drug taken by many of the 1 million people with the condition. Parkinson's disease, a degenerative disease of the central nervous ...
Click on the link to read the full article at MedCity News (This link will open in a new window)OTC Volume Watch List: Solo International, Inc. (OTC:SLIO) and Generex ...
24 January 2013
New York, NY -- (SBWIRE) -- 01/24/2013 -- Growing Stock Report iniates an OTC Volume Watch List and Investor Polls for the following stocks: Solo International, Inc. (OTC:SLIO) and Generex Biotechnology Corp. (OTC:GNBT) Solo International, Inc.
Click on the link to read the full article at SBWire (press release) (This link will open in a new window)Generex Biotechnology Corporation's Oral-lyn Phase III Dossier submitted for ...
24 January 2013
Jan 24, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Drug delivery company Generex Biotechnology Corporation GNBT revealed on Wednesday the submission of a dossier of the results of the Phase III trial of its Generex Oral-lyn seeking approval of the ...
Click on the link to read the full article at MENAFN.COM (This link will open in a new window)
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
